Welcome to our dedicated page for Heron Therapeutics news (Ticker: HRTX), a resource for investors and traders seeking the latest updates and insights on Heron Therapeutics stock.
Heron Therapeutics, Inc. reports commercial and financial developments for a commercial-stage biotechnology business focused on acute care and oncology products. News commonly covers revenue performance and guidance for the Acute Care franchise, including ZYNRELEF and APONVIE, as well as oncology product updates involving CINVANTI and the broader product portfolio.
Company updates also address APONVIE’s role as an FDA-approved IV NK-1 receptor antagonist for prevention of postoperative nausea and vomiting in adults, ZYNRELEF product-handling initiatives for hospital and ambulatory surgical center use, distribution and sales-force activity, intellectual-property matters, and board or governance changes.
Heron Therapeutics, Inc. (HRTX) announced its financial results for Q4 and FY 2021, reporting net product sales of $20.7 million and $86.3 million, respectively. The net loss decreased to $54.6 million for Q4 2021, improving from $62.3 million in Q4 2020. Key highlights include the successful launch of ZYNRELEF, now covering 7 million procedures annually, with net sales reaching $2.9 million. Anticipated guidance for Q1 2022 oncology care franchise sales is $20 million to $22 million. The company aims to moderate cash usage as sales grow.
Heron Therapeutics (HRTX) announced a conference call on February 28, 2022, at 4:30 p.m. ET to discuss its fourth quarter and full year 2021 financial results along with recent business developments. The call can be accessed via phone or webcast on Heron's website. The company aims to enhance patient care through innovative treatments and is committed to addressing unmet medical needs in acute care and oncology. Further details will be available during the call and afterwards on Heron's website.
Heron Therapeutics (HRTX) announced FDA approval for a supplemental New Drug Application for ZYNRELEF, expanding its use in adults for postoperative pain management after various surgeries. This approval enhances ZYNRELEF's indication for up to 72 hours of pain relief in approximately 7 million procedures annually, positioning it as a leading alternative to opioids. The clinical data show ZYNRELEF's superior efficacy over the standard bupivacaine solution. Additionally, reimbursement for the drug now covers up to 120 million lives, broadening its market potential.
Heron Therapeutics (Nasdaq: HRTX) announced the submission of a New Drug Application (NDA) for HTX-019, an injectable emulsion of aprepitant aimed at preventing postoperative nausea and vomiting (PONV) in adults. The NDA includes data supporting the bioequivalence of HTX-019 32 mg IV injection to 40 mg oral aprepitant. This formulation offers faster and more reliable drug exposure, addressing the significant unmet need for effective PONV prevention. Aprepitant is the only NK1 receptor antagonist approved for this indication, with potential benefits for millions of surgical patients annually.
Heron Therapeutics (Nasdaq: HRTX) announced its participation in upcoming investor conferences, focusing on enhancing patient care through innovative treatments. At the Jefferies London Healthcare Conference on November 18-19, 2021, a fireside chat will be available on-demand. Additionally, during the 4th Annual Evercore ISI HealthCONx Conference from November 30 - December 2, 2021, a live fireside chat is scheduled for December 1 at 2:40 PM ET. Webcasts of these events can be accessed via the Company's website.
Heron Therapeutics reported Q3 2021 financial results, with net product sales of $23.2 million, a rise from $20.0 million in Q3 2020. The company achieved $65.7 million in net sales for the nine months ended September 30, 2021, compared to $68.0 million the prior year. ZYNRELEF, launched July 2021, generated $2.1 million in sales, with strong formulary approvals. Despite a net loss of $52.4 million for Q3 2021, down from $58.2 million in Q3 2020, cash reserves were $202.8 million as of September 30, 2021. Future guidance suggests moderated cash usage and potential sales growth in 2022.
Heron Therapeutics (Nasdaq: HRTX) will host a conference call on November 3, 2021, at 4:15 p.m. ET to discuss their third quarter 2021 financial results and recent business highlights. The call is accessible via phone for domestic and international callers and will also be available as a webcast on Heron's website. An archive will be provided for 60 days. Heron focuses on developing innovative treatments to meet unmet patient needs in acute care and oncology.
Heron Therapeutics, Inc. (Nasdaq: HRTX) submitted a supplemental New Drug Application (NDA) to the FDA for its product ZYNRELEF, expanding its indication to include foot and ankle, small-to-medium open abdominal, and lower extremity joint surgeries without the need for additional studies. This followed a successful Type C meeting with the FDA, which allows for two sequential NDA submissions. The company aims to significantly increase the number of indicated procedures, targeting up to 14 million surgeries. ZYNRELEF is the first extended-release local anesthetic approved for postoperative pain management.
Heron Therapeutics, Inc. (Nasdaq: HRTX) announced that Barry Quart, CEO, and John Poyhonen, President, will engage in a fireside chat at the 2021 Cantor Virtual Global Healthcare Conference. The event is scheduled for September 27, 2021, at 1:20 pm ET. A live webcast will be accessible via the company's website, with a replay available for 60 days post-event. Heron Therapeutics focuses on developing advanced treatments to meet significant unmet patient needs in acute care and oncology. For further details, visit www.herontx.com.
Heron Therapeutics (HRTX) reported financial results for Q2 and H1 2021, highlighting a net loss of $61 million and $113.6 million, respectively. Net product sales for oncology care amounted to $22.4 million in Q2, slightly down from $22.7 million a year prior. ZYNRELEF, a new product launched in July 2021, saw positive early adoption with 61 unique accounts placing orders. However, the company faces challenges in growth projections due to reduced cancer patient treatments amid the pandemic and increased competition. Cash reserves stand at $257.7 million, reflecting a strategic preparation for product launches.